Global Briefs: Biogen, AstraZeneca & More 
By

By
A roundup of bio/pharmaceutical news from Biogen/Stoke Therapeutics, AstraZeneca/Fibrogen and Boehringer Ingelheim.  Partnering News * Biogen, Stoke In $550-M Pact for Rare-Disease Anti-Seizure Drug M&A News * AstraZeneca To Acquire Fibrogen China in…

Novartis To Acquire Anthos Therapeutics in $3.3-Bn Deal 
By

By
Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage bio/pharmaceutical company, in a deal worth up to $3.3 billion ($925 million upfront and $2.15 billion in milestone payments).  Anthos…

Bain Capital To Acquire Mitsubishi Tanabe Pharma for $3.3 Bn 
By

By
Bain Capital has agreed to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a Osaka, Japan-based bio/pharmaceutical company, and its subsidiaries in a carve-out transaction from MTPC’s parent company, Mitsubishi Chemical Group…

Supplier News: Axplora, Bio X Cell, SK pharmteco & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Axplora, Bio X Cell, SK pharmteco, Roquette and Frontier Scientific.   Chemicals/Chemical API Manufacturing * SK pharmteco Completes Expansion of HPAPI Analytical Testing Lab Biologics…

M&A News: Merck KGaA, Oramed & More 
By

By
The latest news on mergers and acquisitions featuring Merck KGaA/SpringWorks Therapeutics and Oramed Pharmaceuticals/Hefei Tianhui Biotech. Highlights below.  * Merck KGaA Confirms In Talks for Potential Acquisition of Rare-Disease Drug…

Partnering News: AbbVie, Lilly, Xilio & More 
By

By
A roundup of bio/pharmaceutical partnering news from AbbVie/Xilio Therapeutics, Eli Lilly and Company/AdvanCell and Eli Lilly and Company/OliX.  * AbbVie, Xilio Therapeutics In $2.1-Bn Immunotherapy Oncology Drug Pact * Lilly, AdvanCell…

BMS Announces an Additional $2-Bn Cost-Cutting Plan 
By

By
Bristol Myers Squibb (BMS) has announced that it plans to cut an additional $2 billion in costs by the end of 2027, which is in addition to a previously announced…

Daiichi Sanyko Names New CEO 
By

By
Daiichi Sankyo has appointed Hiroyuki Okuzawa, currently the company’s President and Chief Operating Officer, to succeed Sunao Manabe, currently Daiichi Sankyo’s  Executive Chairperson and CEO, effective April 1, 2025.   Dr.…

Supplier News: SK pharmteco, Ardena, Jabil & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring SK pharmteco, Ardena, Jabil, Pii, AGC Pharma Chemicals, Recipharm, TriLink and Avantor.   Chemicals/Chemical API Manufacturing * SK pharmteco Opens HPAPI Lab  * AGC…

Mfg News: Valneva & Alvogen 
By

By
A roundup of manufacturing news from Valneva and Alvogen. Highlights below.  * Valenva in $33-M Contract with US Gov’t for Encephalitis Vaccine Supply* Alvogen Issues Voluntary Recall of One Lot of…